- A multicenter, randomized, open-label, phase III study of anlotinib plus CAPEOX versus bevacizumab plus CAPEOX as first-line therapy in patients with RAS/BRAF wild-type metastatic colorectal cancerDing, K.; Liu, Y.; Song, Y.; Xu, D.; Li, J.; Wang, J.; Chen, X.; Lin, R.; Jiang, Y.; Zhang, Y.; Zhang, W.; Cheng, Y.; Wu, X.; Yuan, Y.Annual Meeting of the European-Society-for-Medical-Oncology (ESMO), ELECTR NETWORK, 2022-09-09 To 2022-09-13.
- Metformin plus lrinotecan in patients with refractory colorectal cancer: a phase 2 clinical trialArinilda Campos, Bragagnoli; Raphael L. C., Araujo; Mauricio Wagner, Ferraz; Lucas Vieira, dos Santos; Kathia Cristina, Abdalla; Fabiana, Comar; Florinda Almeida, Santos; Marco Antonio, Oliveira; José Barreto Campello, Carvalheira; Flávio Mavigner, Cárcano; João Paulo, da Silveira Nogueira LimaBritish Journal of Cancer, 2021, 124(6): 1072-1078.
- A randomized, open-label, multicenter, phase III study of high-dose vitamin C plus FOLFOX plus /- bevacizumab versus FOLFOX plus /- bevacizumab as first-line treatment in patients with unresectable metastatic colorectal cancerWang, F.; Xiao, J.; Zhang, Y.; Yuan, X.; He, M.; Fang, W.; Zhang, Y.; Wang, W.; Hu, X.; Ma, Z.; Yao, Y.; Zhuang, Z.; Zhou, F.; Ying, J.; Yuan, Y.; Zou, Q.; Guo, Z.; Wu, X.; Jin, Y.; Mai, Z.; Guo, Y.; Xu, R.ESMO 24th World Congress on Gastrointestinal Cancer, Barcelona, SPAIN, 2022-06-29 To 2022.
会议论文
CPGJ602 plus mFOLFOX6 as first-line treatment for patients with KRAS/NRAS/BRAF wild-type metastatic colorectal cancer: A randomized phase II study.
13阅读
